Serving the Society Since 1986
Advanced Search
Volume 36 Issue 3
June 2021
    Citation: Xingui Tian, Ye Fan, Changbing Wang, Zhenwei Liu, Wenkuan Liu, Yun Xu, Chuncong Mo, Aiping You, Xiao Li, Xia Rong, Rong Zhou. Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China .VIROLOGICA SINICA, 2021, 36(3) : 373-381.  http://dx.doi.org/10.1007/s12250-020-00307-1
    shu

    Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China

    cstr: 32224.14.s12250-020-00307-1
    • 1.

      State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510182, China

    • 2.

      Central Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510180, China

    • 3.

      Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou 510095, China

    • Corresponding author: Xia Rong, zhourong@gird.cn, ORCID: http://orcid.org/0000-0002-2463-6340
      Rong Zhou, joyjoy@126.com, ORCID: http://orcid.org/0000-0001-7322-3561
    • Xingui Tian, Ye Fan and Changbing Wang contributed equally to this work.
    • Received Date: 29 June 2020
      Accepted Date: 31 August 2020
      Published Date: 09 November 2020
      Available online: 01 June 2021

    • Human adenoviruses (HAdVs) commonly cause many diseases such as respiratory diseases, gastroenteritis, cystitis worldwide. HAdV-3, -7, -4 and emergent HAdV-55 and HAdV-14 are the most important types causing severe respiratory diseases. There is no effective drug available for clinical treatment, and no vaccine available for the general population. Therefore, it is important to investigate the seroprevalence against HAdV for developing novel vaccines and vectors. In this study, we investigated the seroprevalence and titer levels of neutralizing antibodies (NAb) against HAdV-3, -4, -7, -14, -55, and -11 in total 278 healthy populations between 0 months and 49 years of age (228 children and 50 adults) from Guangzhou. In children under the age of 18 years, the seropositive rates were significantly increased against HAdV-3 at 12.07%, 33.96%, and 64.29% and against HAdV-7 at 0%, 18.87%, and 19.05% in age groups of 1–2, 3–5, and 6–17 years, respectively. The seroprevalence was very low (0%~8.1%) for all other four types. In adults aged between 18 and 49 years, HAdV-3, -4, and -7 (>50.00%) were the most common types, followed by HAdV-14 (38.00%), -55 (34.00%), and -11 (24.00%). Adults tended to have high NAb titers against HAdV-4 and -55. HAdV-55-seropositive donors tended to be HAdV-11- and HAdV-14-seropositive. These results indicated the low level of herd immunity against all six HAdV types in young children, and HAdV-14, -55, -11 in adults from Guangzhou City. Our findings demonstrate the importance of monitoring HAdV types and developing vaccines against HAdV for children and adults.

    • 加载中

      1. Bautista-Gogel J, Madsen CM, Lu X, Sakthivel SK, Froh I, Kamau E, Gerber SI, Watson JT, Cooper SS, Schneider E (2020) Outbreak of respiratory illness associated with human adenovirus type 7 among persons attending Officer Candidates School, Quantico, Virginia, 2017. J Infect Dis 221:697-70

      2. Carr MJ, Kajon AE, Lu X, Dunford L, O'Reilly P, Holder P, De Gascun CF, Coughlan S, Connell J, Erdman DD, Hall WW (2011) Deaths associated with human adenovirus-14p1 infections, Europe, 2009-2010. Emerg Infect Dis 17:1402-1408
          doi: 10.3201/1708.101760

      3. Chen M, Zhu Z, Huang F, Liu D, Zhang T, Ying D, Wu J, Xu W (2015) Adenoviruses associated with acute respiratory diseases reported in Beijing from 2011 to 2013. PLoS ONE 10:e0121375
          doi: 10.1371/journal.pone.0121375

      4. Chen S, Tian X (2018) Vaccine development for human mastadenovirus. J Thorac Dis 10:S2280
          doi: 10.21037/jtd.2018.03.168

      5. Chen Y, Liu F, Wang C, Zhao M, Deng L, Zhong J, Zhang Y, Ye J, Jing S, Cheng Z, Guan Y, Ma Y, Sun Y, Zhu B, Zhang Q (2016) Molecular identification and epidemiological features of human adenoviruses associated with acute respiratory infections in hospitalized children in Southern China, 2012-2013. PLoS ONE 11:e0155412
          doi: 10.1371/journal.pone.0155412

      6. Cheng J, Qi X, Chen D, Xu X, Wang G, Dai Y, Cui D, Chen Q, Fan P, Ni L, Liu M, Zhu F, Yang M, Wang C, Li Y, Sun C, Wang Z (2016) Epidemiology and transmission characteristics of human adenovirus type 7 caused acute respiratory disease outbreak in military trainees in East China. Am J Transl Res 8:2331-2342

      7. Coleman KK, Wong CC, Jayakumar J, Nguyen TT, Wong AWL, Yadana S, Thoon KC, Chan KP, Low JG, Kalimuddin S, Dehghan S, Kang J, Shamsaddini A, Seto D, Su YCF, Gray GC (2020) Adenoviral infections in Singapore: should new antiviral therapies and vaccines be adopted? J Infect Dis 221:566-577

      8. Dehghan S, Seto J, Liu EB, Ismail AM, Madupu R, Heim A, Jones MS, Dyer DW, Chodosh J, Seto D (2019) A zoonotic adenoviral human pathogen emerged through genomic recombination amongst human and nonhuman simian hosts. J Virol 93:e00564-e619

      9. Deng J, Qian Y, Zhao LQ, Zhu RN, Sun Y, Tian R (2013) Identification and typing of adenovirus from acute respiratory infections in pediatric patients in Beijing from 2003 to 2012. Bing du xue bao 29:615-620 (In Chinese)

      10. Feng Y, Sun X, Ye X, Feng Y, Wang J, Zheng X, Liu X, Yi C, Hao M, Wang Q, Li F, Xu W, Li L, Li C, Zhou R, Chen L, Feng L (2018) Hexon and fiber of adenovirus type 14 and 55 are major targets of neutralizing antibody but only fiber-specific antibody contributes to cross-neutralizing activity. Virology 518:272-283
          doi: 10.1016/j.virol.2018.03.002

      11. Fu Y, Tang Z, Ye Z, Mo S, Tian X, Ni K, Ren L, Liu E, Zang N (2019) Human adenovirus type 7 infection causes a more severe disease than type 3. BMC Infects Dis 19:36
          doi: 10.1186/s12879-018-3651-2

      12. Gray GC (2020) Adenovirus 4 and 7 vaccine: new body armor for U.S. Marine Corps Officer Trainees. J Infect Dis 221:685-686

      13. Han G, Niu H, Zhao S, Zhu B, Wang C, Liu Y, Zhang M, Yang S, Liu F, Wan C, Zhang Q (2013) Identification and typing of respiratory adenoviruses in Guangzhou, Southern China using a rapid and simple method. Virol Sin 28:103-108
          doi: 10.1007/s12250-013-3308-7

      14. Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J, Geelen E, van der Helm E, Lemckert A, Gillissen G, Verhaagh S, Custers J, Zuijdgeest D, Berkhout B, Bakker M, Quax P, Goudsmit J, Havenga M (2004) Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol 78:13207-13215
          doi: 10.1128/JVI.78.23.13207-13215.2004

      15. Huang G, Yu D, Zhu Z, Zhao H, Wang P, Gray GC, Meng L, Xu W (2013) Outbreak of febrile respiratory illness associated with human adenovirus type 14p1 in Gansu Province, China. Influenza Other Respir Viruses 7:1048-1054
          doi: 10.1111/irv.12118

      16. Kajon AE, Lamson DM, Bair CR, Lu X, Landry ML, Menegus M, Erdman DD, St George K (2018) Adenovirus type 4 respiratory infections among civilian adults, Northeastern United States, 2011-2015(1). Emerg Infect Dis 24:201-209
          doi: 10.3201/eid2402.171407

      17. Kajon AE, Lu X, Erdman DD, Louie J, Schnurr D, George KS, Koopmans MP, Allibhai T, Metzgar D (2010) Molecular epidemiology and brief history of emerging adenovirus 14-associated respiratory disease in the United States. J Infect Dis 202:93-103
          doi: 10.1086/653083

      18. Kajon AE, Moseley JM, Metzgar D, Huong HS, Wadleigh A, Ryan MA, Russell KL (2007) Molecular epidemiology of adenovirus type 4 infections in US military recruits in the postvaccination era (1997-2003). J Infect Dis 196:67-75
          doi: 10.1086/518442

      19. Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH (2005) Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 79:9694-9701
          doi: 10.1128/JVI.79.15.9694-9701.2005

      20. Li J, Lu X, Sun Y, Lin C, Li F, Yang Y, Liang Z, Jia L, Chen L, Jiang B, Wang Q (2018) A swimming pool-associated outbreak of pharyngoconjunctival fever caused by human adenovirus type 4 in Beijing, China. Int J Infect Dis 75:89-91
          doi: 10.1016/j.ijid.2018.08.009

      21. Lin MR, Yang SL, Gong YN, Kuo CC, Chiu CH, Chen CJ, Hsieh YC, Kuo CY, Fang CW, Tsao KC, Huang YC (2017) Clinical and molecular features of adenovirus type 2, 3, and 7 infections in children in an outbreak in Taiwan, 2011. Clin Microbiol Infect 23:110-116
          doi: 10.1016/j.cmi.2016.11.004

      22. Liu T, Zhou Z, Tian X, Liu W, Xu D, Fan Y, Liao J, Gu S, Li X, Zhou R (2018) A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55. Vaccine 36:2199-2206
          doi: 10.1016/j.vaccine.2018.02.050

      23. Lu QB, Tong YG, Wo Y, Wang HY, Liu EM, Gray GC, Liu W, Cao WC (2014) Epidemiology of human adenovirus and molecular characterization of human adenovirus 55 in China, 2009-2012. Influenza Other Respir Viruses 8:302-308
          doi: 10.1111/irv.12232

      24. Lynch JP 3rd, Kajon AE (2016) Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention. Semin Respir Crit Care Med 37:586-602
          doi: 10.1055/s-0036-1584923

      25. Numazaki Y, Kumasaka T, Yano N, Yamanaka M, Miyazawa T, Takai S, Ishida N (1973) Further study on acute hemorrhagic cystitis due to adenovirus type 11. N Engl J Med 289:344-347
          doi: 10.1056/NEJM197308162890704

      26. Qiu H, Li X, Tian X, Zhou Z, Xing K, Li H, Tang N, Liu W, Bai P, Zhou R (2012) Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions. J Virol 86:7964-7975
          doi: 10.1128/JVI.07076-11

      27. Sandkovsky U, Vargas L, Florescu DF (2014) Adenovirus: current epidemiology and emerging approaches to prevention and treatment. Curr Infect Dis Rep 16:416
          doi: 10.1007/s11908-014-0416-y

      28. Scott MK, Chommanard C, Lu X, Appelgate D, Grenz L, Schneider E, Gerber SI, Erdman DD, Thomas A (2016) Human adenovirus associated with severe respiratory infection, Oregon, USA, 2013-2014. Emerg Infect Dis 22:1044-1051
          doi: 10.3201/eid2206.151898

      29. Seto D, Chodosh J, Brister JR, Jones MS, Members of the Adenovirus Research C (2011) Using the whole-genome sequence to characterize and name human adenoviruses. J Virol 85:5701-5702
          doi: 10.1128/JVI.00354-11

      30. Stone D, Ni S, Li ZY, Gaggar A, DiPaolo N, Feng Q, Sandig V, Lieber A (2005) Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol 79:5090-5104
          doi: 10.1128/JVI.79.8.5090-5104.2005

      31. Tan D, Zhu H, Fu Y, Tong F, Yao D, Walline J, Xu J, Yu X (2016) Severe community-acquired pneumonia caused by human adenovirus in immunocompetent adults: a multicenter case series. PLoS ONE 11:e0151199
          doi: 10.1371/journal.pone.0151199

      32. Tian X, Chen Y, Li H, Fan Y, Zhou Z, Chen S, Li X, Zhou R (2019) Characterization of a replication-competent vector encoding DsRed based on a human adenovirus type 4 a-like strain. Virus Res 270:197662
          doi: 10.1016/j.virusres.2019.197662

      33. Tian X, Jiang Z, Fan Y, Qiu S, Zhang L, Li X, Zhou Z, Liu T, Ma Q, Lu X (2018) A tetravalent vaccine comprising hexon-chimeric adenoviruses elicits balanced protective immunity against human adenovirus types 3, 7, 14 and 55. Antivir Res 154:17-25
          doi: 10.1016/j.antiviral.2018.04.001

      34. Tian X, Jiang Z, Ma Q, Liu Q, Lu X, Liu W, Liao X, Zhou R, Su X, Luo Q (2016) Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China. J Thorac Dis 8:803
          doi: 10.21037/jtd.2016.03.29

      35. Tian X, Ma Q, Jiang Z, Huang J, Liu Q, Lu X, Luo Q, Zhou R (2015) Identification and application of neutralizing epitopes of human adenovirus type 55 hexon protein. Viruses 7:5632-5642
          doi: 10.3390/v7102896

      36. Tian X, Su X, Xue C, Li X, Zhou Z, Zhou R (2014) Antigenic variability among two subtypes of human adenovirus serotype 7. Virus Genes 49:22-29
          doi: 10.1007/s11262-014-1071-y

      37. Walsh MP, Seto J, Jones MS, Chodosh J, Xu W, Seto D (2010) Computational analysis identifies human adenovirus type 55 as a re-emergent acute respiratory disease pathogen. J Clin Microbiol 48:991-993
          doi: 10.1128/JCM.01694-09

      38. Xie L, Zhang B, Xiao N, Zhang F, Zhao X, Liu Q, Xie Z, Gao H, Duan Z, Zhong L (2019) Epidemiology of human adenovirus infection in children hospitalized with lower respiratory tract infections in Hunan, China. J Med Virol 91:392-400
          doi: 10.1002/jmv.25333

      39. Yao L-h, Wang C, Wei T-l, Wang H, Ma F-l, Zheng L-s (2019) Human adenovirus among hospitalized children with respiratory tract infections in Beijing, China, 2017-2018. Virol J 16:78
          doi: 10.1186/s12985-019-1185-x

      40. Ye X, Xiao L, Zheng X, Wang J, Shu T, Feng Y, Liu X, Su W, Wang Q, Li C, Chen L, Feng L (2018) Seroprevalence of neutralizing antibodies to human adenovirus Type 4 and 7 in healthy populations from southern China. Front Microbiol 9:3040
          doi: 10.3389/fmicb.2018.03040

      41. Yu Z, Zeng Z, Zhang J, Pan Y, Chen M, Guo Y, Yu N, Chodosh J, Fu N, Che X, Zhang Q (2016) Fatal community-acquired pneumonia in children caused by re-emergent human adenovirus 7d associated with higher severity of illness and fatality rate. Sci Rep 6:37216
          doi: 10.1038/srep37216

      42. Zhang J, Kang J, Dehghan S, Sridhar S, Lau SKP, Ou J, Woo PCY, Zhang Q, Seto D (2019) A survey of recent adenoviral respiratory pathogens in Hong Kong Reveals emergent and recombinant human adenovirus type 4 (HAdV-E4) circulating in civilian populations. Viruses 11:129
          doi: 10.3390/v11020129

      43. Zheng X, Rong X, Feng Y, Sun X, Li L, Wang Q, Wang M, Liu W, Li C, Yang Y, Zhou R, Lu J, Feng L, Chen L (2017) Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China. Emerg Microbes Infect 6:e43

    • 加载中

    Figures(4) / Tables(3)

    PDF

    Article Metrics

    Article views(23468) PDF downloads(24) Cited by()

    Related
    Proportional views

      Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China

        Corresponding author: Xia Rong, zhourong@gird.cn
        Corresponding author: Rong Zhou, joyjoy@126.com
      • 1. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510182, China
      • 2. Central Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510180, China
      • 3. Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou 510095, China
      • Received Date: 29 June 2020
      • Accepted Date: 31 August 2020
      • Published Date: 09 November 2020

      Abstract: 

      Human adenoviruses (HAdVs) commonly cause many diseases such as respiratory diseases, gastroenteritis, cystitis worldwide. HAdV-3, -7, -4 and emergent HAdV-55 and HAdV-14 are the most important types causing severe respiratory diseases. There is no effective drug available for clinical treatment, and no vaccine available for the general population. Therefore, it is important to investigate the seroprevalence against HAdV for developing novel vaccines and vectors. In this study, we investigated the seroprevalence and titer levels of neutralizing antibodies (NAb) against HAdV-3, -4, -7, -14, -55, and -11 in total 278 healthy populations between 0 months and 49 years of age (228 children and 50 adults) from Guangzhou. In children under the age of 18 years, the seropositive rates were significantly increased against HAdV-3 at 12.07%, 33.96%, and 64.29% and against HAdV-7 at 0%, 18.87%, and 19.05% in age groups of 1–2, 3–5, and 6–17 years, respectively. The seroprevalence was very low (0%~8.1%) for all other four types. In adults aged between 18 and 49 years, HAdV-3, -4, and -7 (>50.00%) were the most common types, followed by HAdV-14 (38.00%), -55 (34.00%), and -11 (24.00%). Adults tended to have high NAb titers against HAdV-4 and -55. HAdV-55-seropositive donors tended to be HAdV-11- and HAdV-14-seropositive. These results indicated the low level of herd immunity against all six HAdV types in young children, and HAdV-14, -55, -11 in adults from Guangzhou City. Our findings demonstrate the importance of monitoring HAdV types and developing vaccines against HAdV for children and adults.

        HTML

      Introduction